With an 8.3% compound annual growth rate (CAGR), the global Graft Versus Host Disease Treatment Market Size is expected to reach US$ 5,655.37 million by 2032. The market has been progressively rising due to the increased usage of corticosteroids and combination drugs to treat Graft Versus Host Disease in hematopoietic cell transplant (HCT) patients. The market value is estimated to be US$ 2,547.86 million in 2022, representing a 7.8% increase from 2016 to 2021.
Recent improvements in overall survival and acute Graft Versus Host Disease severity levels have benefited patients receiving allogeneic hematopoietic cell transplant, although several challenges remain. Newer treatments, including as Jakafi and Rezurock, have been approved for the prevention and treatment of chronic Graft Versus Host Disease, and they may be more effective than previous medications.
Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-1401
The US Food and Drug Administration authorised Orencia (abatacept) in December 2021 for the treatment of GRAFT VERSUS HOST DISEASE in adults and paediatric patients. Orencia can not only treat but also prevent autoimmune illnesses. Orencia inhibits acute Graft Versus Host Disease by attaching to and regulating one of the most important costimulation signals given by T-cells. Doctors are now testing innovative methods for preventing Graft Versus Host Disease in the future.
Orencia’s clearance is likely to enhance access to stem cell transplants for a greater number of cancer patients and people with blood disorders, particularly those from various ethnic backgrounds. Immunosuppression and other medications such as regenerative or tissue-repairing drugs may be used in the future to improve therapy response in Graft Versus Host Disease patients.
Key Takeaways
- North America is expected to lead the global graft versus host disease (Graft Versus Host Disease) therapy market throughout the projected period, according to the study.
- According to the analysis, Europe will be the second-largest market over the predicted year.
- Adoption of various Graft Versus Host Disease treatments is expected to drive the industry and account for the majority of the market in 2022.
- According to Future Market Insights, monoclonal antibodies are projected to gain a significant market share in the next years.
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-1401
Regional Insights:
According to the report, North America is predicted to lead the worldwide graft versus host disease (Graft Versus Host Disease) treatment market over the forecast period. The region is expected to account for approximately 34% of the global market share in 2022. The presence of major important players in the region, as well as a well-established medical infrastructure, have contributed to its supremacy in the (Graft Versus Host Disease) therapy market.
During the projection period, the United States is expected to be the greatest contributor to market development, owing to rising awareness of Graft Versus Host Disease and the availability of new treatments that are expected to boost market expansion. The regulatory approval of several drugs is also expected to help the region thrive.
During the forecast period, Europe is expected to be the second-largest market, accounting for 21% of total market share in 2022. The rapid development of the region’s food and beverage sector can be ascribed to the market’s growth throughout Europe.
Competition Analysis:
Key players in the global graft versus host disease (Graft Versus Host Disease) treatment market include Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH,Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others.
- Equillium, Inc. has announced that the EQUATOR study, a pivotal Phase 3 clinical research of itolizumab in patients with acute graft-versus-host disease (Graft Versus Host Disease), will begin in March 2022. Itolizumab will be compared to placebo as first-line therapy for (Graft Versus Host Disease) in combination with corticosteroids in a randomised, double-blind study.
- Novartis stated that Jakavi (ruxolitinib) would be approved by the European Commission (EC) in May 2022 for the treatment of patients aged 12 and older with acute or chronic (Graft Versus Host Disease) who have not responded effectively to corticosteroids or other systemic treatments. With Jakavi, a revolutionary strategy for controlling (Graft Versus Host Disease) that is debilitating and life-threatening is now possible, providing healthcare practitioners and patients with a new option.
Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/1401
Key Segments Profiled In The Global Graft Versus Host Disease Treatment Market:
Graft Versus Host Disease Treatment Market by Product:
- Monoclonal antibodies Graft Versus Host Disease Treatment
- mTOR inhibitors Graft Versus Host Disease Treatment
- Tyrosine kinase inhibitors Graft Versus Host Disease Treatment
- Thalidomide Graft Versus Host Disease Treatment
- Etanercept Graft Versus Host Disease Treatment
Graft Versus Host Disease Treatment Market by Disease:
- Acute Graft Versus Host Disease
- Chronic Graft Versus Host Disease
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
